|  New Generation Drug Discovery Software Enters Market  Released on = October 25, 2005, 11:06 am  Press Release Author = Quantum Pharmaceuticals  Industry = Biotech  Press Release Summary = Quantum Pharmaceuticals is issuing its first commercial
  release of research software that is expected to speed up pharma R&D radically and
              irrevocably change the drug discovery software market.  Press Release Body = Quantum 3.1 is a suite of drug discovery software for Linux and
              Windows designed to enhance stages of drug discovery workflows, such as target
              identification, drug hit identification, lead identification and lead optimization.  The Quantum software was developed using a new paradigm in molecular modeling –
              applying quantum and molecular physics instead of statistical scoring-function-like
              and QSAR-like methods.  The key benefit of Quantum is the outstanding precision of molecular modeling and
              calculations. Using Quantum 3.1, researchers can calculate the IC50 of
              protein-ligand and protein-protein complexes, perform ligand docking, perform
              virtual screening of small-molecule libraries, analyze large-scale protein
              movements, perform de novo drug design and calculate the solvation energy and
              solubility.  Quantum 3.1 also helps detect potential moderate-to-serious adverse activity,
              additional unexpected activity and broad relative selectivity for a library of
              compounds by screening them against several hundred ADME/TOX-associated proteins.  The Mutagenesis module of Quantum 3.1 provides an interface for changing the protein
              sequence at specific sites through alterations to its amino acids and predicts
              changes in the bioactivity after mutations.  The Quantum software was successfully applied in different in-house and
              collaborative drug discovery projects of Quantum Pharmaceuticals. As a result of
              applying Quantum software, the range of the novel chemical inhibitor classes were
              discovered for disease targets, including HIV-I integrase (AIDS), Beta-Secretase(Alzheimer’s disease), Human Neutrophil Elastase (CF, COPD), FtsZ (TB) and some
              others. Quantum technology has demonstrated itself to be very effective in creating
              revolutionary new medicine, and it has demonstrated its ability to discover new
              classes of inhibitors.
 The free demo version of Quantum 3.1 can be downloaded from Quantum's web site. 
 About Quantum Pharmaceuticals 
 Quantum Pharmaceuticals, the leader in drug discovery technology, serves the life
              sciences industry and research community by providing top-of-the-line drug discovery
              products and services.  Since 2002 Quantum Pharmaceuticals has been developing its superior proprietary
              computer-based molecular modeling technology. The Quantum technology includes the
              latest achievements in the fields of physics, mathematics and chemistry. It
              demonstrates outstanding speed and accuracy of affinity calculations using fastquantum calculations which take into account the full flexibility of molecules,
              solvation effects and entropy contribution. This provides unprecedented
              possibilities for drug discovery.
 The headquarters of Quantum Pharmaceuticals is in Moscow, and its worldwide
              distribution network is expanding.  www.q-pharm.com
 Web Site = http://www.q-pharm.com  Contact Details = office@q-pharm.comtel 70951529615
 
            
              
                                      Printer 
              Friendly Format
            Back 
              to previous page...
            Back 
              to home page...
            Submit 
              your press releases...
  
                  |